Loading…
← CockpitCompetitor Analysis › EPIGRAL.NS Epigral LtdOpen in the cockpit ↗

Epigral LtdEPIGRAL.NSCompetitor analysis, valuation and peers

India · INR·Chemicals›Chemicals: Agricultural
Momentum laggard 17
Mkt cap
$435M
US dollars, full cap
Free float
29%
of shares outstanding
$/day
$581,698
20-day average traded
Fwd P/E
13.2×
forward earnings
ROIC−WACC
-6.8 pp
WACC 17.4%
Hurdle
n/a
no reverse DCF
Next earnings
69 days
26 Jan 2027
Close · INR₹944.30
1D-0.3%
1W+0.4%
1M-3.7%
3M-12.5%
6M-23.8%
YTD-22.6%
1Y-38.3%
ATR %3.8%
Beta1.31
52w lowhigh38.6% off high

What Epigral does

Employees: 2,319

Epigral at a glance

Size Epigral (EPIGRAL.NS) is an India Materials company (Chemicals: Agricultural) with a market value of $435M, the 912th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹944.30 on 18 Nov 2026.

Performance Over six months the shares fell 23.8%, against -24.4% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 12.9% over the last twelve months (peer median +4.2%); the operating margin is 14.9% (peer median 2.9%).

Valuation It trades at 13.2× forward earnings against a peer median of 13.8× (5th cheapest of 9).

Capital Return on invested capital runs 6.8 points below its cost of capital (17.4% WACC).

Next results Next results expected around 26 Jan 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 77EPIGRAL.NS 76
Six months, rebased to 100: Epigral against the median of its 20 peers (local-currency closes).

Epigral financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹27.8B₹25.0B₹25.2B₹19.0B₹21.7B
Revenue growth—-1%+33%-13%—
Gross profit₹6.72B₹4.63B₹6.62B₹4.05B₹6.43B
EBITDA₹5.87B₹5.50B₹6.87B₹4.56B₹6.77B
Net income₹2.85B₹3.32B₹3.58B₹1.96B₹3.53B
Free cash flown/a-₹65.3M₹1.80B-₹727M₹1.50B
Capital expendituren/a₹3.94B₹1.95B₹3.98B₹4.16B
Total debt₹5.70B₹5.72B₹5.93B₹9.64B₹8.79B

Quarterly statements and history in the cockpit →

Epigral competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%-15%-10%-5%600731002391603639RALLIS49966039700024961712300575ATT4997603334603585600228600470300804NFL1708EPIGRAL.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Epigral is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%10×20×30×002391603639RALLIS4996603970300575603585002556EPIGRAL.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Epigral is the large dot.

Epigral competitors and peer comparison

How Epigral compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Epigral against its 20 peers (data as of 18 Nov 2026)
MeasureEPIGRAL.NSPeer medianRank in peer set
1-month return-3.7%-11.9%3rd highest of 21
6-month return-23.8%-24.4%10th highest of 21
Distance from 52-week high-38.6%-36.0%9th lowest of 21
Revenue growth (TTM)+12.9%+4.2%5th highest of 21
Operating margin14.9%2.9%2nd highest of 21
Forward P/E13.2×13.8×5th cheapest of 9
ROIC minus cost of capital-6.8 pp-1.3 pp5th lowest of 21
EV / EBITDA7.9×6.7×3rd most expensive of 6
Net debt / EBITDA1.0×0.7×5th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Epigral EPIGRAL.NSIndia$435M-24%+13%15%13.2×n/an/a
Hunan Haili Chemical Industry 600731.SSChina$438M-16%-24%11%n/a-6.6%-3.6%
Jiangsu Changqing Agrochemical 002391.SZChina$441M-25%-2%3%32.8×n/an/a
Hailir Pesticides & Chemicals 603639.SSChina$453M-24%-9%1%6.0×n/an/a
Rallis India RALLIS.NSIndia$394M-25%+7%10%17.6×20.3%+3.6%
Kumiai Chemical Industry 4996.TJapan$487M-18%+7%4%10.0×-8.6%+9.7%
Sino-Agri Leading Biosciences 603970.SSChina$385M-23%+1%2%9.0×-11.7%+11.1%
Jiangsu Huifeng Bio Agriculture 002496.SZChina$378M-28%+40%-31%n/an/an/a
Sinon 1712.TWTaiwan$502M-4%+4%7%n/a-4.6%+1.3%
Jiangsu Flag Chemical Industry 300575.SZChina$375M-24%+21%1%26.4×0.3%+7.5%
Grupa Azoty Spolka Akcyjna ATT.WAPoland$372M-31%-3%-4%n/an/an/a
Nihon Nohyaku 4997.TJapan$509M+7%+5%11%n/a-8.8%+9.3%
Suzhou Fengbei Biotech Stock 603334.SSChina$517M-48%+63%4%n/an/an/a
Suli 603585.SSChina$361M-32%+1%6%9.7×n/an/a
Jiangxi Fanli Digital Technology 600228.SSChina$529M+45%+89%-7%n/a-13.5%+2.0%
Zhejiang XinNong Chemical 002942.SZChina$355M-26%+10%9%n/a5.0%-1.4%
Anhui Liuguo Chemical 600470.SSChina$346M-29%-10%-9%n/an/an/a
Yingde Greatchem Chemicals 300804.SZChina$343M-27%-9%1%n/an/an/a
National Fertilizers NFL.NSIndia$332M-16%+4%3%n/an/an/a
Anhui Huilong Agricultural Means of Production .Co 002556.SZChina$572M-25%0%1%18.3×8.4%-1.2%
Sesoda 1708.TWTaiwan$330M+15%+11%19%n/a-10.7%+8.8%

Questions

Which companies are Epigral's closest peers?
The cockpit's peer set: Hunan Haili Chemical Industry (600731.SS), Jiangsu Changqing Agrochemical (002391.SZ), Hailir Pesticides & Chemicals (603639.SS), Rallis India (RALLIS.NS), Kumiai Chemical Industry (4996.T), Sino-Agri Leading Biosciences (603970.SS), Jiangsu Huifeng Bio Agriculture (002496.SZ), Sinon (1712.TW).
Is Epigral expensive compared with its peers?
On forward p/e it trades at 13.2× against a peer median of 13.8×, 5th cheapest of 9 in its peer set.
How has Epigral stock performed?
Over six months to 18 Nov 2026 the shares returned -23.8% against -24.4% for the median peer; over one year -38.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.